Whiteside Theresa L, Demaria Sandra, Rodriguez-Ruiz Maria E, Zarour Hassane M, Melero Ignacio
Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Radiation Oncology, University of Cornell, New York, New York.
Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049.
Immunotherapy strategies against cancer are emerging as powerful weapons for treatment of this disease. The success of checkpoint inhibitors against metastatic melanoma and adoptive T-cell therapy with chimeric antigen receptor T cells against B-cell-derived leukemias and lymphomas are only two examples of developments that are changing the paradigms of clinical cancer management. These changes are a result of many years of intense research into complex and interrelated cellular and molecular mechanisms controling immune responses. Promising advances come from the discovery of cancer mutation-encoded neoantigens, improvements in vaccine development, progress in delivery of cellular therapies, and impressive achievements in biotechnology. As a result, radical transformation of cancer treatment is taking place in which conventional cancer treatments are being integrated with immunotherapeutic agents. Many clinical trials are in progress testing potential synergistic effects of treatments combining immunotherapy with other therapies. Much remains to be learned about the selection, delivery, and off-target effects of immunotherapy used alone or in combination. The existence of numerous escape mechanisms from the host immune system that human tumors have evolved still is a barrier to success. Efforts to understand the rules of immune cell dysfunction and of cancer-associated local and systemic immune suppression are providing new insights and fuel the enthusiasm for new therapeutic strategies. In the future, it might be possible to tailor immune therapy for each cancer patient. The use of new immune biomarkers and the ability to assess responses to therapy by noninvasive monitoring promise to improve early cancer diagnosis and prognosis. Personalized immunotherapy based on individual genetic, molecular, and immune profiling is a potentially achievable future goal. The current excitement for immunotherapy is justified in view of many existing opportunities for harnessing the immune system to treat cancer.
针对癌症的免疫治疗策略正成为治疗这种疾病的有力武器。检查点抑制剂治疗转移性黑色素瘤的成功,以及嵌合抗原受体T细胞过继性T细胞疗法治疗B细胞源性白血病和淋巴瘤的成功,只是正在改变临床癌症管理模式的众多进展中的两个例子。这些变化是多年来对控制免疫反应的复杂且相互关联的细胞和分子机制进行深入研究的结果。有前景的进展来自癌症突变编码新抗原的发现、疫苗开发的改进、细胞疗法递送方面的进步以及生物技术领域令人瞩目的成就。因此,癌症治疗正在发生根本性转变,传统癌症治疗正与免疫治疗药物相结合。许多临床试验正在进行,以测试免疫疗法与其他疗法联合使用的潜在协同效应。关于单独或联合使用免疫疗法的选择、递送和脱靶效应,仍有许多需要了解的地方。人类肿瘤进化出的众多逃避宿主免疫系统的机制仍然是成功的障碍。了解免疫细胞功能障碍以及癌症相关的局部和全身免疫抑制规则的努力正在提供新的见解,并激发了对新治疗策略的热情。未来,有可能为每位癌症患者量身定制免疫疗法。使用新的免疫生物标志物以及通过非侵入性监测评估治疗反应的能力有望改善癌症的早期诊断和预后。基于个体遗传、分子和免疫谱分析的个性化免疫疗法是一个潜在可实现的未来目标。鉴于利用免疫系统治疗癌症目前存在诸多机会,当前对免疫疗法的兴奋是合理的。